Upsized Offerings Boost Medtech IPO Uptick
Executive Summary
The public markets are receptive to medtech stock, with the first half of this year recording more – and bigger – medtech IPOs than a year ago.
You may also be interested in...
BioTrinity 2018: Bullish M&A And IPO Outlook; Spotlight On Eyevensys, Rexgenero
Industry experts, investors and start-ups from across the pharma, biotech and medtech sectors gathered at the recent annual BioTrinity conference held in London to hear how the capital-raising climate is looking rosy for 2018, and to explore partnering and investment opportunities. Medtech Insight reports on predicted trends in health care and highlights two companies, Eyevensys and Rexgenero, that were presenting at the conference.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.